Navigation Links
NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region
Date:7/22/2009

DUBAI, United Arab Emirates and SAN FRANCISCO, July 22 /PRNewswire/ -- NewBridge Pharmaceuticals, a specialty pharmaceutical, biologics, and medical device company serving the Middle East, Africa, Turkey & Caspian regions, today announced that it has entered into an exclusive license and supply agreement with Axcan Pharma for Pylera(R), an innovative 3-in-1 capsule therapy for the eradication of Helicobacter pylori, a bacterium now recognized as being the main cause of gastric and duodenal ulcers. Pursuant to the agreement, NewBridge is entitled to obtain exclusive rights in certain markets where it obtains required regulatory approvals and launches the product. The product should be launched in Q4 2010.

Pylera(R), which was developed by Axcan over the last ten years, is a patented 3-in-1 capsule therapy. Each Pylera(R) capsule contains bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride. Pylera(R) is clinically proven to be as effective as the most widely prescribed therapeutic regimen for the eradication of Helicobacter pylori (omeprazole, amoxicillin and clarithromycin) and has the potential to be used in a wide range of patients as a first-line therapy for the eradication of Helicobacter pylori based on its convenient 10-day treatment dosing regimen. Pylera(R) provides additional clinical benefit by improving patient compliance. Pylera(R) received FDA approval in September 2006 and was successfully launched in the United States in May 2007.

"In partnering with Axcan for the Pylera 3-in-1 capsule therapy for Helicobacter pylori eradication, NewBridge Pharmaceuticals advances further to become one of the key providers of innovative pharmaceutical care to the Middle East, Turkey, CIS and Africa," said Dr. Garrett Vygantas, CEO of NewBridge Pharmaceuticals. "NewBridge's strategy of providing world-cla
'/>"/>

SOURCE NewBridge Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Newbridge Securities Corporation Forms BioVentures Division
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... Inc. (NASDAQ: GNVC ) today announced the retirement ... of directors effective on October 24, 2014.   Dr. Horovitz joined ... chairman from June 2006 to November 2013.  During his tenure, ... Audit Committees of the board.  "We deeply ... to GenVec, and its stockholders," said Wayne T. Hockmeyer ...
(Date:10/20/2014)... 2014 Earle Martin , ... today that Ellen Teplitzky, an experienced attorney specializing ... pharmaceutical industry, has joined the firm as Director ... services practice. NDA Partners provides legal services, ... testimony, to top law firms and their clients ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th Annual ... take place at the Congress Center Basel, ... now available at http://www.abim.ch . ... from all over the globe will exchange ... products and developments on the world market. ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... June 30 Celsis In Vitro, Inc. (Celsis ... infringement lawsuit against Invitrogen Corporation (Invitrogen) and CellzDirect, Inc. ... Northern District of Illinois in Chicago ... the parent of CellzDirect, is itself a wholly-owned subsidiary ...
... showcasing pharmaceutical, biotechnological and medical device employers in areas ranging from Niagara Falls to ... (Logo: http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO ) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040907/CLTU006LOGO ) , ... The leading employment Web site for the life sciences launched the ...
... TargeGen, Inc., a privately held biotechnology company focused on ... the Company has agreed to be acquired by sanofi-aventis (EURONEXT: ... will depend on the achievement of certain future milestones events ... fully realized. The closing of the transaction is expected to ...
Cached Biology Technology:Celsis Seeks Injunction Against Invitrogen for LiverPool(TM) Patent Infringement 2Celsis Seeks Injunction Against Invitrogen for LiverPool(TM) Patent Infringement 3BioSpace Promotes the Northeast Corridor's Life Science Industry 2BioSpace Promotes the Northeast Corridor's Life Science Industry 3Sanofi-aventis to Acquire TargeGen, Inc. 2
(Date:10/17/2014)... regarding Ebola is critical and pertinent for practicing physicians ... outbreak and epidemic. The Journal, Disaster Medicine and ... Ebola Virus and Public Health, to surround the public, ... critical societal moment. , On October 17, the ... . The primer was prepared by Dr. Eric Toner, ...
(Date:10/16/2014)... the human body. Battles are won, lost or ... this stalemate—known as tumor dormancy—can last up to ... that is poorly understood. , A new ... Torquato, a Professor of Chemistry at Princeton University, ... and the switch to a malignant state. Published ...
(Date:10/16/2014)... monocultures can be cultivated efficiently, they are anything ... caused by monoculture cultivation is becoming increasingly evident. ... crop form and are regarded as the sole ... – quite wrongfully, finds Bernhard Schmid, an ecology ... a novel form of agriculture and forestry. After ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... mating systems, reproductive success reflects phenotypic variation. At ... that of body size and weapon morphology, as ... In a study published in the September issue ... Arizona University) and Jerry F. Husak (Oklahoma State ...
... step toward developing a new type of ultra-sensitive medical ... the skin to detect tiny gold nanorods injected into ... yielded images nearly 60 times brighter than conventional fluorescent ... of biological imaging to study the inner workings of ...
... "shooting stars" of their field. Many research scientists have been ... the blood into diseased organs and replace defective tissue. Such ... of certain muscle diseases. However, a study currently being conducted ... the cells are able to migrate into the muscle fibres, ...
Cached Biology News:Purdue's gold nanorods brighten future for medical imaging 2Research casts doubt on circulating stem cells 2Research casts doubt on circulating stem cells 3
... linear ion trap mass spectrometer enables high-throughput ... The LXQ linear ion trap mass spectrometer ... applications, delivering the fast cycle time and ... trap at an attractive price. The ...
The Synergy HT utilizes a unique dual-optics design combined with monochromator wavelength selection to provide uncompromised performance in absorbance, fluorescence and luminescence reading modes. ...
... short-term enriched housing for nonhuman primates and ... non-quarantine settings on a per diem basis. ... state-of-the-art social housing and nursery facilities. In ... CDC quarantine facilities. Primate housing and ...
... some the things youll be telling others after ... by Erica Golemis, One look at the table ... topics in protein interaction will tell you immediately ... a part of your personal protein chemistry library. ...
Biology Products: